Koskenvesa, Perttu

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Porkka, K., Koskenvesa, P., Lundán, T., Rimpiläinen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., et al. (2008) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 445

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., Hehlmann, R., Faber, E., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 96

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, F.-X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., et al. (2024) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 71

Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

Adnan Awad, S., Kankainen, M., Ojala, T., Koskenvesa, P., Eldfors, S., Ghimire, B., Kumar, A., Kytölä, S., Kamel, M. M., Heckman, C. A., et al. (2020) · Blood Advances

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 67

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

Lauseker, M., Bachl, K., Turkina, A., Faber, E., Prejzner, W., Olsson‐Strömberg, U., Baccarani, M., Lomaia, E., Zackova, D., Ossenkoppele, G., et al. (2019) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 28

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Richter, J., Lübking, A., Söderlund, S., Lotfi, K., Markevärn, B., Själander, A., Stenke, L., Deneberg, S., Ahlstrand, E., Myhr-Eriksson, K., et al. (2021) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 27

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmäki, H., Koskenvesa, P., Kallioniemi, O., et al. (2015) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 25

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Flygt, H., Söderlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., Majeed, W., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, F., Mahon, F.-X., Richter, J., Piciocchi, A., Cipriani, M., Nicolini, F. E., Mayer, J., Zackova, D., Janssen, J. J. W. M., Panayiotidis, P., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsCancer survivorship and care

Cited by 15

Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study

Flygt, H., Söderlund, S., Stentoft, J., Richter, J., Koskenvesa, P., Mustjoki, S., Majeed, W., Lübking, A., Dreimane, A., Markevärn, B., et al. (2021) · European Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 11